Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 20

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
.9)Inventory(0.9)(1.8)Prepaid taxes2.1 (1.4)Other assets0.5 0.2 Accounts payable— 6.1 Accrued liabilities(12.4)(14.6)Net cash used in operating activities(16.3)(18.6)CASH FLOWS FROM INVESTING ACTIVITIES:Capital expenditures(5.3)(6.7)Capitalization of intangible assets(3.0)(1.9)Proceeds from maturities and sales of marketable investment securities— 1.5 Net cash used in investing activities(8.3)(7.1)CASH FLOWS FROM FINANCING ACTIVITIES:Payment of tax withheld for common stock issued under stock-based compensation plans(5.8)(8.7)Proceeds from revolving credit facility40.0 60.0 Repayment of revolving credit facility(20.5)(60.0)Payment on finance leases(0.1)(0.1)Net cash provided by (used in) financing activities13.6 (8.8)Effect of foreign exchange rates on cash, cash equivalents, and restricted cash0.1 (0.8)Net decrease in cash, cash equivalents, and restricted cash(10.9)(35.3)Cash, cash equivalents, and restricted cash at beginning of the period111.9 140.9 Cash, cash equivalents, and restricted cash at end of the period$101.0 $105.6 

See accompanying notes to Condensed Consolidated Financial Statements.

8

Table of Contents

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1.BASIS OF PRESENTATION

Myriad Genetics, Inc. (together with its subsidiaries, the “Company” or “Myriad”) is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower health care costs. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. The Company’s principal executive office is located in Salt Lake City, Utah.The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with